ESMO Congress 2025
Is it time to shift supportive care toward digital-assisted approaches?
Recent findings show digital tools have the potential to improve the monitoring of symptoms and psychological aspects, but they should be integrated within routine clinical practice
New artificial intelligence-based biomarkers offer early insight into treatment response
Findings from four studies provide further evidence on the potential of AI-driven pathology, imaging and multiomic data to guide clinical decision-making
Novel strategies to overcome resistance to immune checkpoint inhibitors show promise in early studies
Blocking GDF-15, an mRNA-based therapy and targeting VISTA have a strong mechanistic rationale, resulting in clinical benefit in heavily pre-treated patients
New directions in metastatic mutated NSCLC
Precision targeting, immune modulation and rational trial design are converging to improve patient outcomes
Survival improvements observed with first-line antibody–drug conjugates in triple-negative breast cancer
TROP2-targeted ADCs, sacituzumab govitecan and datopotamab deruxtecan, meet their primary endpoints in phase III trials
Innovative strategies lead to mixed benefits for rare cancers
Positive findings are presented for advanced Merkel-cell carcinoma plus phaeochromocytoma and paragangliomas, while negative findings are equally important to guide future research
First-in-human trial of a TCR-T therapy targeting KRAS G12V reports a significant response rate
Preliminary results of NW-301V are promising, with a lack of severe adverse effects at all doses tested in patients with pancreatic cancer or colorectal cancer
ctDNA shapes anti-EGFR rechallenge strategies in metastatic colorectal cancer
Recent research shows that molecular monitoring is key to identify a patient-tailored window of opportunity for rechallenge
Research in pancreatic adenocarcinoma targets antibody-drug conjugates and oncolytic viruses
While telisotuzumab adizutecan demonstrated early antitumour activity, only modest benefits were seen with VCN-01 added to standard care
Promising novel strategies to boost anticancer immunity in NECs
Despite the presentation of encouraging study findings with novel immunotherapy-based therapies, long-term outcomes are needed to better understand the magnitude of clinical benefit and many questions remain around off-target toxicity and the identification of patients most likely to respond to treatment